Daniel Faga
Directeur Général chez ANAPTYSBIO, INC.
Fortune : 8 M $ au 30/04/2024
Profil
Actuellement, Daniel R. Faga est vice-président exécutif, directeur de l'exploitation et des finances chez Mirati Therapeutics, Inc. Dans le passé, il a occupé le poste de directeur général chez Centerview Partners LLC et celui de directeur commercial chez Spark Therapeutics, Inc. Il a obtenu un diplôme de premier cycle à l'université Cornell et un MBA à la Wharton School de l'université de Pennsylvanie.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ANAPTYSBIO, INC.
1,50% | 01/04/2024 | 401 646 ( 1,50% ) | 8 M $ | 30/04/2024 |
Postes actifs de Daniel Faga
| Sociétés | Poste | Début |
|---|---|---|
| ANAPTYSBIO, INC. | Directeur Général | 21/03/2022 |
Affini-T Therapeutics, Inc.
 Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Directeur/Membre du Conseil | 05/04/2022 |
Anciens postes connus de Daniel Faga
| Sociétés | Poste | Fin |
|---|---|---|
| MIRATI THERAPEUTICS | Directeur Financier/CFO | 01/11/2021 |
| SPARK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2019 |
Centerview Partners LLC
 Centerview Partners LLC Investment Banks/BrokersFinance Centerview Partners LLC is a registered broker/dealer headquartered in New York City. The firm was founded by Robert Pruzan in 2006 and is a subsidiary of Centerview Partners Advisory Holdings LLC. Centerview Partners provides brokerage services to companies, institutions and governments. | Corporate Officer/Principal | 01/04/2016 |
Formation de Daniel Faga
| Cornell University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ANAPTYSBIO, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Centerview Partners LLC
Centerview Partners LLC Investment Banks/BrokersFinance Centerview Partners LLC is a registered broker/dealer headquartered in New York City. The firm was founded by Robert Pruzan in 2006 and is a subsidiary of Centerview Partners Advisory Holdings LLC. Centerview Partners provides brokerage services to companies, institutions and governments. | Finance |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Health Technology |
